WVE
Wave Life Sciences Ltd. [WVE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
WVE Stock Summary
Top 10 Correlated Stocks
WVE
In the News
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the 6th Annual Evercore ISI HealthCONx Conference in Miami, FL on Wednesday, November 29, 2023 at 3:50 p.m. ET.
Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Kate Rausch - Vice President, Investor Relations & Corporate Affairs Paul Bolno - President & Chief Executive Officer Anne-Marie Li-Kwai-Cheung - Chief Development Officer Kyle Moran - Chief Financial Officer Conference Call Participants Steve Seedhouse - Raymond James Salim Syed - Mizuho Joseph Schwartz - Leerink Partners Eun Yang - Jefferies Operator Good morning and welcome to Wave Life Sciences Third Quarter 2023 Financial Results Conference Call.
Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan 7th Annual Genetic Medicines Conference in New York City on Monday, October 2, 2023. Dr. Bolno will participate in the ADAR Editing Panel at 9:30 a.m. ET and an analyst-led fireside chat at 10:30 a.m. ET.
2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss
Gene-editing therapies are among the most powerful medicines to ever exist. Wave Life Sciences is taking aim at two rare diseases, but it's short on cash.
Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash
Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 trials for Duchenne muscular dystrophy and Huntington's Disease. Wave has collaborations with GSK and Takeda, with the GSK deal potentially worth up to $3.3 billion in milestone payments.
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a virtual analyst-led fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference. The presentation will be available to view beginning on Monday, September 11, 2023, at 7:00 a.m. ET.
WAVE Life Sciences Ltd. Sees a 23% Stock Price Surge Over the Past Three Months
WAVE Life Sciences Ltd. ( WVE , Financial), a preclinical biopharmaceutical company, has seen a significant increase in its stock price over the past three months.
Wave Life Sciences Ltd. (WVE) Q2 2023 Earnings Call Transcript
Wave Life Sciences Ltd. (NASDAQ:WVE ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President and Chief Executive Officer Anne Cheung - Chief Development Officer Kyle Moran - CFO Conference Call Participants Steven Seedhouse - Raymond James Julian Pino - Stifel Eun Yang - Jefferies Salim Syed - Mizuho Operator Good morning, and welcome to the Wave Life Sciences Second Quarter 2023 Financial Results Conference Call.
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
Wave Life Sciences (WVE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.62 per share a year ago.
WVE Financial details
WVE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.5 | 0.47 | 0.51 | 0.79 | 0.05 | |
| Net income per share | -5.06 | -5.3 | -3.82 | -2.36 | -2.05 | |
| Operating cash flow per share | -0.79 | -5.56 | -2.96 | -1.72 | -1.62 | |
| Free cash flow per share | -1.13 | -5.67 | -2.99 | -1.73 | -1.64 | |
| Cash per share | 6.03 | 4.35 | 4.7 | 2.91 | 1.12 | |
| Book value per share | 2.53 | 1.88 | 2.11 | 0.63 | -0.57 | |
| Tangible book value per share | 2.53 | 1.88 | 2.11 | 0.63 | -0.57 | |
| Share holders equity per share | 2.53 | 1.88 | 2.11 | 0.63 | -0.57 | |
| Interest debt per share | 0.36 | 0.96 | 0.75 | 0.58 | 0.46 | |
| Market cap | 1.22B | 271.61M | 308.72M | 162.73M | 551.99M | |
| Enterprise value | 1.05B | 157M | 153.53M | 42.08M | 501.11M | |
| P/E ratio | -8.3 | -1.51 | -2.06 | -1.33 | -3.41 | |
| Price to sales ratio | 84.5 | 16.99 | 15.38 | 3.97 | 151.27 | |
| POCF ratio | -53.27 | -1.44 | -2.66 | -1.83 | -4.32 | |
| PFCF ratio | -37.13 | -1.41 | -2.63 | -1.82 | -4.27 | |
| P/B Ratio | 16.6 | 4.26 | 3.73 | 5.01 | -12.24 | |
| PTB ratio | 16.6 | 4.26 | 3.73 | 5.01 | -12.24 | |
| EV to sales | 73.09 | 9.82 | 7.65 | 1.03 | 137.33 | |
| Enterprise value over EBITDA | -6.7 | -0.74 | -1 | -0.33 | -3.08 | |
| EV to operating cash flow | -46.08 | -0.83 | -1.32 | -0.47 | -3.92 | |
| EV to free cash flow | -32.12 | -0.82 | -1.31 | -0.47 | -3.88 | |
| Earnings yield | -0.12 | -0.66 | -0.49 | -0.75 | -0.29 | |
| Free cash flow yield | -0.03 | -0.71 | -0.38 | -0.55 | -0.23 | |
| Debt to equity | 0.14 | 0.51 | 0.35 | 0.92 | -0.83 | |
| Debt to assets | 0.04 | 0.11 | 0.1 | 0.14 | 0.26 | |
| Net debt to EBITDA | 1.05 | 0.54 | 1.01 | 0.95 | 0.31 | |
| Current ratio | 1.56 | 1.57 | 1.9 | 2.53 | 1.38 | |
| Interest coverage | -7.25K | 0 | 9.59K | 0 | 103.12 | |
| Income quality | 0.16 | 0.97 | 0.77 | 0.73 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.74 | 3.06 | 2.12 | 1.13 | 13.84 | |
| Research and developement to revenue | 9.33 | 10.98 | 6.52 | 2.98 | 31.75 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.43 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Capex to revenue | -0.69 | -0.25 | -0.07 | -0.01 | -0.37 | |
| Capex to depreciation | -1.78 | -0.43 | -0.13 | -0.06 | -0.13 | |
| Stock based compensation to revenue | 1.08 | 1.22 | 0.71 | 0.4 | 4.71 | |
| Graham number | 16.98 | 14.98 | 13.47 | 5.77 | 5.14 | |
| ROIC | -1.7 | -1.5 | -1.08 | -1.37 | -5.42 | |
| Return on tangible assets | -0.5 | -0.63 | -0.54 | -0.59 | -1.11 | |
| Graham Net | -1.39 | -1.58 | 0.4 | -0.46 | -1.31 | |
| Working capital | 72.23M | 67.32M | 109M | 98.36M | 27.02M | |
| Tangible asset value | 73.35M | 63.73M | 82.78M | 32.5M | -45.09M | |
| Net current asset value | -20.32M | -35.04M | 33.58M | -11.95M | -92.94M | |
| Invested capital | 0.14 | 0.51 | 0.35 | 0.92 | -0.83 | |
| Average receivables | 5.5M | 15M | 25M | 15M | 0 | |
| Average payables | 10.34M | 11.08M | 11.43M | 10.54M | 12.1M | |
| Average inventory | 0 | 4.81M | 10.03M | 5.22M | 0 | |
| Days sales outstanding | 253.23 | 456.74 | 545.4 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 1.44 | 0.8 | 0.67 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -2 | -2.82 | -1.81 | -3.76 | 3.59 | |
| Capex per share | -0.34 | -0.12 | -0.03 | -0.01 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.01 | 0.13 | 0.21 | 0.46 | |
| Net income per share | -0.42 | -0.47 | -0.24 | -0.2 | 0.07 | |
| Operating cash flow per share | -0.27 | -0.36 | 0.84 | -0.35 | -0.32 | |
| Free cash flow per share | -0.28 | -0.36 | 0.83 | -0.35 | -0.33 | |
| Cash per share | 1.3 | 0.94 | 2.03 | 1.64 | 1.32 | |
| Book value per share | -0.05 | -0.48 | -0.34 | -0.49 | -0.38 | |
| Tangible book value per share | -0.05 | -0.48 | -0.34 | -0.49 | -0.38 | |
| Share holders equity per share | -0.05 | -0.48 | -0.34 | -0.49 | -0.38 | |
| Interest debt per share | 0.41 | 0.38 | 0.33 | 0.33 | 0.32 | |
| Market cap | 338.98M | 657.96M | 441.91M | 383.88M | 609.64M | |
| Enterprise value | 280.62M | 607.07M | 270.96M | 246.07M | 503.37M | |
| P/E ratio | -2.17 | -3.76 | -4.5 | -4.55 | 21.02 | |
| Price to sales ratio | 1.19K | 531.04 | 34.18 | 17.37 | 12.39 | |
| POCF ratio | -13.22 | -19.68 | 5.17 | -10.3 | -17.69 | |
| PFCF ratio | -12.99 | -19.56 | 5.2 | -10.28 | -17.59 | |
| P/B Ratio | -75.01 | -14.59 | -12.73 | -7.42 | -15.06 | |
| PTB ratio | -75.01 | -14.59 | -12.73 | -7.42 | -15.06 | |
| EV to sales | 984.64 | 489.97 | 20.96 | 11.13 | 10.23 | |
| Enterprise value over EBITDA | -7.61 | -13.94 | -9.12 | -9.57 | 113.27 | |
| EV to operating cash flow | -10.94 | -18.15 | 3.17 | -6.6 | -14.61 | |
| EV to free cash flow | -10.75 | -18.04 | 3.19 | -6.59 | -14.53 | |
| Earnings yield | -0.12 | -0.07 | -0.06 | -0.05 | 0.01 | |
| Free cash flow yield | -0.08 | -0.05 | 0.19 | -0.1 | -0.06 | |
| Debt to equity | -8.54 | -0.83 | -1.05 | -0.68 | -0.83 | |
| Debt to assets | 0.21 | 0.26 | 0.14 | 0.15 | 0.17 | |
| Net debt to EBITDA | 1.58 | 1.17 | 5.75 | 5.36 | -23.91 | |
| Current ratio | 2.05 | 1.38 | 1.66 | 1.32 | 1.59 | |
| Interest coverage | -370.47 | 25.88 | 10.52 | 0 | 0 | |
| Income quality | 0.66 | 0.77 | -3.12 | 1.77 | -4.75 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 40.73 | 11.08 | 0.95 | 0.55 | 0.27 | |
| Research and developement to revenue | 96.75 | 25.08 | 2.4 | 1.51 | 0.64 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.01 | -0.01 | 0 | 0.01 | |
| Capex to revenue | -1.6 | -0.16 | -0.04 | 0 | 0 | |
| Capex to depreciation | -0.18 | -0.08 | -0.2 | -0.03 | -0.09 | |
| Stock based compensation to revenue | 11.81 | 2.35 | 0.21 | 0.11 | 0.05 | |
| Graham number | 0.67 | 2.24 | 1.36 | 1.49 | 0.77 | |
| ROIC | -0.54 | -1.47 | -0.7 | -0.99 | 0.15 | |
| Return on tangible assets | -0.22 | -0.3 | -0.09 | -0.09 | 0.04 | |
| Graham Net | -0.68 | -1.1 | -0.93 | -1.03 | -0.86 | |
| Working capital | 67.18M | 27.02M | 87.03M | 44.48M | 58.59M | |
| Tangible asset value | -4.52M | -45.09M | -34.71M | -51.72M | -40.49M | |
| Net current asset value | -54.6M | -92.94M | -82.39M | -97M | -81.83M | |
| Invested capital | -8.54 | -0.83 | -1.05 | -0.68 | -0.83 | |
| Average receivables | 0 | 0 | 0 | 0 | 3.5M | |
| Average payables | 13.55M | 16.42M | 14.41M | 12.14M | 12.49M | |
| Average inventory | 0 | 0 | 0 | 0 | 3.76M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 12.8 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 7.03 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 8.65 | 0.97 | 0.71 | 0.41 | -0.18 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
WVE Frequently Asked Questions
What is Wave Life Sciences Ltd. stock symbol ?
Wave Life Sciences Ltd. is a SG stock and trading under the symbol WVE
What is Wave Life Sciences Ltd. stock quote today ?
Wave Life Sciences Ltd. stock price is $5.12 today.
Is Wave Life Sciences Ltd. stock public?
Yes, Wave Life Sciences Ltd. is a publicly traded company.
Company Profile
- Volume Average 292.61K
- Market Capitalization 525.98M
- Employee 250
- CEO Dr. Paul B. Bolno M.B.A., M.D.
- Headquarters Singapore,SG
- IPO Date 2015-11-11
-
Website
https://www.wavelifesciences.com 
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
